Efficacy, safety, tolerability and treatment durability of microneedling plus topical tranexamic acid in combination with topical modified Kligman lightening formula for melasma: A four-arm assessor and analyst blinded randomized controlled clinical trial.
Melasma
device assisted drug delivery
microneedling
modified Kligman formula
tranexamic acid
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
received:
25
05
2024
accepted:
01
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
17
7
2024
Statut:
aheadofprint
Résumé
The challenging management of melasma highlights the inadequacies of conventional therapies and their high risk of recurrence. Integrating microneedling for device-assisted drug delivery with tranexamic acid (TA), recognized for its melanin synthesis inhibition, presents a novel approach that warrants further investigation to fully assess its potential in enhancing melasma treatment efficacy. Fifty moderate to severe melasma patients participated in this randomized outcome-assessor-blinded controlled trial. Patients were randomly allocated into two main groups. Group A received a modified Kligman formula on one hemi-face on alternate nights for 2 months (A1) and three sessions of microneedling with 10% topical TA on the other hemi-face at 1-month intervals (A2). Group B used the same modified Kligman formula on both sides of the face, with one side additionally receiving three sessions of microneedling with 4% TA (B1) and the opposite side with 10% TA (B2). Primary outcomes were % Modified Melasma Area and Severity Index (mMASI) and % visual analogue scale (VAS) change during 6 month follow-up. Adverse events including post-inflammatory hyperpigmentation (PIH) and treatment tolerability were recorded. Compared to baseline, the mean mMASI reduction immediately after the final session was higher in A1, B1, and B2 (56.84%, 50.88%, and 55.87%, respectively) than in A2, which saw only a 13.16% reduction. Efficacy notably declined after the cessation of treatment across all groups. While the efficacy within groups A1, B1, and B2 was comparable, microneedling with 4% or 10% TA combined with the topical modified Kligman formula proved more potent in patients at a lower risk of PIH. Overall, 22% of patients reported PIH, particularly in the A2 group (28% of hemi-faces), with its occurrence significantly associated with treatment during warmer seasons and in darker skin phototypes. Other adverse events were not observed in any patient. Patient satisfaction was highest in groups B1 and B2, where approximately 72% reported 'excellent' satisfaction. The lowest durability rate (16%) was observed in group A2, while the highest (72%) was seen in group B2, comparable with groups A1 and B1. Treatment tolerability was reported 100% in all groups. It was found that the modified Kligman formula outperformed microneedling-TA alone. However, with optimal patient selection, particularly targeting those at lower risk for PIH with lighter skin phototypes and scheduling treatments during less-sunny seasons, combining microneedling with 4% or 10% TA and the modified Kligman formula significantly enhanced efficacy and satisfaction rates compared to conventional topical treatment.
Sections du résumé
BACKGROUND
BACKGROUND
The challenging management of melasma highlights the inadequacies of conventional therapies and their high risk of recurrence. Integrating microneedling for device-assisted drug delivery with tranexamic acid (TA), recognized for its melanin synthesis inhibition, presents a novel approach that warrants further investigation to fully assess its potential in enhancing melasma treatment efficacy.
METHODS
METHODS
Fifty moderate to severe melasma patients participated in this randomized outcome-assessor-blinded controlled trial. Patients were randomly allocated into two main groups. Group A received a modified Kligman formula on one hemi-face on alternate nights for 2 months (A1) and three sessions of microneedling with 10% topical TA on the other hemi-face at 1-month intervals (A2). Group B used the same modified Kligman formula on both sides of the face, with one side additionally receiving three sessions of microneedling with 4% TA (B1) and the opposite side with 10% TA (B2). Primary outcomes were % Modified Melasma Area and Severity Index (mMASI) and % visual analogue scale (VAS) change during 6 month follow-up. Adverse events including post-inflammatory hyperpigmentation (PIH) and treatment tolerability were recorded.
RESULTS
RESULTS
Compared to baseline, the mean mMASI reduction immediately after the final session was higher in A1, B1, and B2 (56.84%, 50.88%, and 55.87%, respectively) than in A2, which saw only a 13.16% reduction. Efficacy notably declined after the cessation of treatment across all groups. While the efficacy within groups A1, B1, and B2 was comparable, microneedling with 4% or 10% TA combined with the topical modified Kligman formula proved more potent in patients at a lower risk of PIH. Overall, 22% of patients reported PIH, particularly in the A2 group (28% of hemi-faces), with its occurrence significantly associated with treatment during warmer seasons and in darker skin phototypes. Other adverse events were not observed in any patient. Patient satisfaction was highest in groups B1 and B2, where approximately 72% reported 'excellent' satisfaction. The lowest durability rate (16%) was observed in group A2, while the highest (72%) was seen in group B2, comparable with groups A1 and B1. Treatment tolerability was reported 100% in all groups.
CONCLUSION
CONCLUSIONS
It was found that the modified Kligman formula outperformed microneedling-TA alone. However, with optimal patient selection, particularly targeting those at lower risk for PIH with lighter skin phototypes and scheduling treatments during less-sunny seasons, combining microneedling with 4% or 10% TA and the modified Kligman formula significantly enhanced efficacy and satisfaction rates compared to conventional topical treatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Abdalla MA. Melasma clinical features, diagnosis, epidemiology and etiology: an update review. Siriraj Medical Journal. 2021;73(12):841‐850.
Ogbechie‐Godec OA, Elbuluk N. Melasma: an up‐to‐date comprehensive review. Dermatol Ther (Heidelb). 2017;7(3):305‐318.
Sarkar R, Arora P, Garg VK, Sonthalia S, Gokhale N. Melasma update. Indian Dermatol Online J. 2014;5(4):426‐435.
Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55(6):1048‐1065.
Mahajan VK, Patil A, Blicharz L, et al. Medical therapies for melasma. J Cosmet Dermatol. 2022;21(9):3707‐3728.
Sunder S. Relevant topical skin care products for prevention and treatment of aging skin. Facial Plast Surg Clin North Am. 2019;27(3):413‐418.
Iranmanesh B, Khalili M, Mohammadi S, Amiri R, Aflatoonian M. The efficacy of energy‐based devices combination therapy for melasma. Dermatol Ther. 2021;34(3):e14927.
Austin E, Nguyen JK, Jagdeo J. Topical treatments for melasma: a systematic review of randomized controlled trials. J Drugs Dermatol. 2019;18(11):S1545961619P1156X.
Liu Y, Wu S, Wu H, Liang X, Guo D, Zhuo F. Comparison of the efficacy of melasma treatments: a network meta‐analysis of randomized controlled trials. Front Med. 2021;8:713554.
Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. Efficacy and safety of tranexamic acid in melasma: a meta‐analysis and systematic review. Acta Derm Venereol. 2017;97(7):776‐781.
Cassiano D, Esposito ACC, Hassun K, et al. Efficacy and safety of microneedling and oral tranexamic acid in the treatment of facial melasma in women: an open, evaluator‐blinded, randomized clinical trial. J Am Acad Dermatol. 2020;83(4):1176‐1178.
Majid I. Mometasone‐based triple combination therapy in melasma: is it really safe? Indian J Dermatol. 2010;55(4):359‐362.
Kaur A, Bhalla M, Pal Thami G, Sandhu J. Clinical efficacy of topical tranexamic acid with microneedling in melasma. Dermatologic Surg. 2020;46(11):e96‐e101.
Lachenbruch PA, Cohen J. Statistical power analysis for the behavioral sciences. J Am Stat Assoc. 1989;84(408):1096.
Poostiyan N, Alizadeh M, Shahmoradi Z, Fatemi NF. Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: a randomized assessor‐blind split‐face controlled trial. J Cosmet Dermatol. 2023;22(4):1238‐1244.
Shamsi Meymandi S, Mozayyeni A, Shamsi Meymandi M, Aflatoonian M. Efficacy of microneedling plus topical 4% tranexamic acid solution vs 4% hydroquinone in the treatment of melasma: a single‐blind randomized clinical trial. J Cosmet Dermatol. 2020;19(11):2906‐2911.
Kuster Kaminski Arida D, Orso Rebellato PR, Marioto de Campos GL, et al. Randomized, double‐blind, placebo‐controlled split‐face trial of the efficacy of tranexamic acid by drug delivery through microneedling in the treatment of melasma. J Cosmet Dermatol. 2021;20(12):4005‐4010.
Menon A, Eram H, Kamath PR, Goel S, Babu AM. A split face comparative study of safety and efficacy of microneedling with tranexamic acid versus microneedling with vitamin C in the treatment of melasma. Indian Dermatol Online J. 2019;11(1):41‐45.